Search

Displaying results 6061 - 6070 of 6189 in total
  1. Drug

    Prinomastat

    go.drugbank.com/drugs/DB05100
    Investigational

    Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, ...

  2. Drug

    PTI-801

    go.drugbank.com/drugs/DB05300
    Investigational

    PTI-801 can minimize the opioid tolerance, dependence or addiction that is often associated with repeat use of oxycodone.

  3. Drug

    Rusalatide

    go.drugbank.com/drugs/DB05309
    Investigational

    TP508 is a non-proteolytic synthetic peptide representing the portion of human thrombin originally identified as the fibroblast high-affinity receptor binding domain.

  4. Drug

    ACR-16

    go.drugbank.com/drugs/DB05371
    Investigational

    ACR-16 is under investigation by NeuroSearch. ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within ...

  5. Drug

    CP-122721

    go.drugbank.com/drugs/DB05421
    Experimental

    CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.

  6. Drug

    MLN-977

    go.drugbank.com/drugs/DB05431
    Experimental

    MLN-977 is a small molecule compound that inhibits the production of leukotrienes, especially 5-lipoxygenase. It is developed by PharmaEngine to treat asthma and chronic obstructive pulmonary disease.

  7. Drug

    INO-1001

    go.drugbank.com/drugs/DB05549
    Investigational

  8. Drug

    Apilimod

    go.drugbank.com/drugs/DB05611
    Investigational

  9. Drug

    Sarizotan

    go.drugbank.com/drugs/DB06454
    Investigational

  10. Drug

    Cinalukast

    go.drugbank.com/drugs/DB00587
    Experimental

    Used in the treatment of asthma, cinalukast selectively antagonizes leukotriene D4 (LTD4) at the cysteinyl leukotriene receptor, CysLT1, in the human airway. … Cinalukast inhibits the actions of LTD4 at the CysLT1 receptor, preventing airway edema, smooth muscle contraction, and enhanced secretion of thick, viscous mucus.